imlunestrant

News

Lily gets FDA nod for SERD-CDK 4/6 combo in breast cancer

Eli Lilly's imlunestrant (Inluriyo) for breast cancer has received a new FDA approval, in combination with CDK4/6 inhibitor abemaciclib (Verzenio).

News

Lilly brings second oral SERD to market for breast cancer

Lilly's Inluriyo is the second oral SERD to reach the US market for ESR1-mutated breast cancer, setting up a market tussle with Menarini's Orserdu.

News

Data cues up AZ oral SERD filing in first-line breast cancer

AstraZeneca could be the first to bring an oral SERD to market in first-line breast cancer after camizestrant hit the mark in a phase 3 trial.

News

End of the line for Sanofi's SERD amcenestrant as it fails f...

Sanofi has called time on breast cancer candidate amcenestrant – at one time one of its top pipeline prospects – after it missed the mark in another clinical trial.

Lily gets FDA nod for SERD-CDK 4/6 combo in breast cancer

Lilly brings second oral SERD to market for breast cancer

Data cues up AZ oral SERD filing in first-line breast cancer

End of the line for Sanofi's SERD amcenestrant as it fails f...

CHMP backs Lilly's oral GLP-1 Foundayo for EU approval

Discover a new era of healthcare panel engagement: Grounded ...

imlunestrant

Editor's Picks